Trial Information
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients
Inclusion Criteria:
- non metastatic Prostate Cancer
- previous treatment with bicalutamide 150mg
- biochemical relapse/progression
Exclusion Criteria:
- use of other treatments for Prostate Cancer
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
Hormonal sensitivity to second line treatment for CaP after Bicalutamide
Outcome Time Frame:
six months
Safety Issue:
No
Principal Investigator
Davide Meani, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca Medical Dept
Authority:
Italy: Ethics Committee
Study ID:
NIS-OIT-CAS-2007/1
NCT ID:
NCT00668083
Start Date:
September 2007
Completion Date:
July 2008
Related Keywords:
- Prostate Cancer
- second line
- Prostate Cancer
- bicalutamide
- biochemical relapse/progression in patients with Prostate Cancer treated with bicalutamide 150mg
- Prostatic Neoplasms